Assessment of MDD Management in Andalusia (PismaEP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01510886
First received: January 12, 2012
Last updated: August 12, 2014
Last verified: August 2014

January 12, 2012
August 12, 2014
June 2012
September 2013   (final data collection date for primary outcome measure)
  • Number of Visits to Primary Care [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Number of Visits to Secondary Care [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Number of Referrals [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01510886 on ClinicalTrials.gov Archive Site
  • Demographics [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Type of site [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Type of therapeutic strategy [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Type of disease [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Severity of disease [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Assessment of MDD Management in Andalusia
Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study

The main objectives of this study are to describe medical professionals responsible of the management of patients with MDD in a representative region of Andalusia (in terms of type of sites managing the disease, and referral to SC criteria); Describe MDD patient characteristics at inclusion in the PISMA-Ep Study; and to evaluate those factors associated to a higher incidence of referral from PC to SC.

Assessment of MDD management strategies in Andalusia: A Sub-analysis of the PismaEP Study

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

MDD patients treated in Primary Care or Secondary Care in the Region of Granada and recruited for the PISMA-Ep Study

MDD Management Strategies
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5309
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • MDD Diagnosis Participants of the PismaEP study 18 yo. or older

Exclusion Criteria:

  • No specific exclusion criteria
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01510886
NIS-NES-XXX-2011/3, PismaEP
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Jorge Cervilla, MD Hospital San Cecilio
AstraZeneca
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP